THOMAS SCIASCIA - 15 Feb 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Scientific Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
15 Feb 2024
Net transactions value
$0
Form type
4
Filing time
16 Feb 2024, 16:42:38 UTC
Previous filing
16 Feb 2023
Next filing
31 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +150,000 $0.000000 150,000 15 Feb 2024 Common Stock 150,000 $2.38 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 15, 2024. The 150,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028.